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Edited by Robert BaroukiAbstract We investigated the eﬀect of oleanolic acid, a plant-
derived triterpenoid, on insulin secretion and content in pancre-
atic b-cells and rat islets. Oleanolic acid signiﬁcantly enhanced
insulin secretion at basal and stimulatory glucose concentrations
in INS-1 832/13 cells and enhanced acute glucose-stimulated
insulin secretion in isolated rat islets. In the cell line the eﬀects
of oleanolic acid on insulin secretion were comparable to that
of the sulfonylurea tolbutamide at basal glucose levels and with
the incretin mimetic Exendin-4 under glucose-stimulated condi-
tions, yet neither Ca2+ nor cAMP rose in response to oleanolic
acid. Chronic treatment with oleanolic acid increased total cellu-
lar insulin protein and mRNA levels. These eﬀects may contrib-
ute to the anti-diabetic properties of this natural product.
 2008 Federation of European Biochemical Societies.
Published by Elsevier B.V. All rights reserved.
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In Type 2 diabetes insuﬃcient insulin is secreted by pancre-
atic b-cells to compensate for insulin resistance. Although a
variety of treatment options exist including compounds that
reduce insulin resistance, reduce hepatic glucose production,
enhance insulin secretion and preserve b-cell function, there
are limitations to the current treatment options [1]. Thus, iden-
tiﬁcation of compounds with anti-diabetic properties that may
have therapeutic potential is still needed.
In alternative medicinal approaches diabetes has been trea-
ted with dietary intake of various herbs and plant-derived ex-
tracts [2]. Recently, several plant-derived natural products
have been identiﬁed that have glucose-lowering eﬀects such
as oleanolic acid and oleanolic acid glycosides. Oleanolic acid
is a triterpenoid found in a variety of plant species. This com-
pound and the related natural product ursolic acid have been
shown to have numerous biological properties with therapeutic
potential (reviewed in [3,4]). Depending on the concentration*Corresponding author. Address: Division of Cell and Molecular
Biology, Toronto General Research Institute, University Health
Network, 101 College Street, TMDT 10-707, Toronto, ON, Canada
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doi:10.1016/j.febslet.2008.03.026used, oleanolic acid has been shown to have anti-inﬂamma-
tory, anti-tumorigenic, anti-viral and hepatoprotective eﬀects.
A number of synthetic oleanane triterpenoid derivatives have
been synthesized based on oleanolic acid with more potent
activities, some of which are currently being developed as ther-
apeutics for cancer treatment [5].
The potential anti-diabetic eﬀects of oleanolic acid and
derivatives and their mechanism of action have been less well
studied. In one study, oleanolic acid glycosides puriﬁed from
plants, but not oleanolic acid itself, reduced serum glucose lev-
els in rats given an oral glucose load [6]. More recent studies
showed that oleanolic acid is able to reduce plasma glucose lev-
els in rats and mice [7,8]. The mechanism of action of oleanolic
acid and oleanolic acid glycosides is not well established. Here
we investigated the eﬀects of acute and chronic treatment with
oleanolic acid on insulin secretion and content in pancreatic b-
cell lines and in isolated rat islets.2. Materials and methods
2.1. Materials
Oleanolic acid and tolbutamide were obtained from Sigma. Olean-
olic acid was dissolved in 95% ethanol at a stock concentration of
10.9 mM. Tolbutamine was dissolved in DMSO at a stock concentra-
tion of 100 mM. Exendin-4 was obtained from Dr. Daniel Drucker
(Mt. Sinai Hospital, Toronto, Canada).
2.2. Cell culture and rat islet isolation
Rat INS-1 (obtained from Dr. Claus Wollheim, University of Gen-
eva) [9] and INS1 832/13 pancreatic b-cells (obtained from Dr. Chris
Newgard, Duke University) [10] were maintained as described in these
references.
Male Wistar rats (250–350 g) were obtained from Charles River Inc.
Rat islets were isolated as described in Ref. [11]. Isolated islets were
cultured in RPMI 1640 media (7.5% FBS, 10 mM HEPES, 5.6 mM
glucose) at 37 C/5% CO2.
2.3. Insulin secretion and content assays
For insulin secretion experiments, INS-1 832/13 cells were plated
onto 12-well plates. After 24 h incubation in RPMI 1640 (5 mM glu-
cose), the cells were washed with HBSS: (114 mM NaCl, 4.7 mM KCl,
1.2 mM KH2PO4, 1.16 mM MgSO4, 20 mM HEPES, 2.5 mM CaCl2,
25.5 mM NaHCO3, pH 7.2, 0.1% BSA) with 3 mM glucose and incu-
bated for 2 h. Cells were then treated for 1 h in HBSS (3 mM glucose)
or (15 mM glucose) with or without oleanolic acid. Cell supernatants
were collected, centrifuged at 5500 rpm, 4 C for 1 min and insulin
was measured by radioimmunoassay (RIA) (Linco Inc.). Cells were
lysed in lysis buﬀer: (1% Triton-X, 20 mM HEPES, pH 7.4, 100 mM
KCl, 2 mM EDTA, 1.0 mM PMSF, with protease inhibitors (Roche)).
Protein concentrations were determined using the BCA assay (Pierce).blished by Elsevier B.V. All rights reserved.
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bated in 1.5 ml tubes at 37 C for 1 h in Krebs Ringer (KRBH) buﬀer:
(128.8 mM NaCl, 4.8 mM KCl, 1.2 mM KH2PO4, 5 mM NaHCO3,
2.5 mM CaCl2, 1.2 mM MgSO4, 10 mM HEPES, 0.2% BSA, pH
7.4) with 2.8 mM glucose. KRBH buﬀer with 2.8 mM glucose or
16.7 mM glucose with or without oleanolic acid was added. After 1 h
samples were placed on ice and centrifuged 5500 rpm, 4 C for
1 min. Supernatants were removed and insulin was measured by
RIA. The islet pellets were lysed in RIPA buﬀer (50 mM Tris–HCl,
pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 1% Sodium
deoxycholate, 0.1% SDS, 1 mM PMSF, 10 lg/ml Aprotinin, 10 lg/ml
Leupeptin) and incubated on ice for 30 min. After centrifugation
(13000 rpm, 4 C for 10 min) the supernatant was removed and sub-
jected to BCA protein assay. Each condition was done in quadrupli-
cate and typically four independent experiments were performed.
For cellular insulin content experiments, INS-1 cells were grown on
24-well plates, treated as described in Fig. 4 legend and total cellular
insulin was measured as described previously [12].
2.4. Glucagon and somatostatin secretion assays
Isolated rat islets were treated as described above. Glucagon (LIN-
CO Research Inc., St. Louis, MO) and somatostatin (Euro-Diagnosti-
ca AB, Malmo¨, Sweden) in islet supernatants were measured by
commercially available radioimmunoassay kits according to the man-
ufacturers instructions. For the somatostatin determination, somato-
statin was ﬁrst extracted from the sample media using Sep-pak C18
cartridges (Waters Corp., Milford, MA, USA) prior to being assayed.
2.5. Total RNA Isolation, cDNA synthesis and real-time PCR
Total RNA was isolated from INS-1 832/13 cells using TRIzol
Reagent (Invitrogen) according to the manufacturers instructions.
Isolated RNA was then applied to RNeasy columns from the RNeasy
RNA Isolation Kit (Qiagen). Total RNA was reverse transcribed to
single-stranded cDNA using the High-Capacity cDNA Reverse Tran-
scription Kit (Applied Biosystems). The cDNA from the reverse tran-
scription reactions was used for ampliﬁcation in real-time PCR.
TaqMan Gene Expression Assays speciﬁc for insulin-2 or b-actin were
used in combination with the TaqMan Universal PCR Master Mix. A
ﬁnal real-time PCR reaction of 25 ll containing 10 ll cDNA, 1.25 ll
ddH2O, 1.25 ll TaqMan Gene Expression Assay (20·), and 12.5 ll
TaqMan Universal PCR Master Mix (2·) was performed in triplicate
in a 96-Well Optical Reaction Plate. Reactions were run on an ABI
Prism 7900HT Sequence Detection System using the following proto-
col: 10 min at 95 C, 40 cycles of 15 s at 95 C and 1 min at 60 C. Rel-
ative target mRNA amounts were determined by a serial dilution
standard curve (10-fold dilutions) according to the manufacturers
instructions. Relative insulin-2 mRNA values were normalized to
expression of rat b-actin mRNA.
2.6. Intracellular calcium measurements
INS-1 832/13 cells were seeded onto 25 mm glass coverslips and
grown overnight. Medium was changed to RPMI 1640 (5 mM glucose)
for 24 h before experimentation. The cells were washed with Buﬀer AOleanolic acid Tolbutamide
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Fig. 1. Eﬀect of oleanolic acid on insulin secretion in INS-1 832/13 b-cells. C
(3 mM glucose) and glucose-stimulated (15 mM glucose) conditions (A), an
secretion was measured by RIA. * denotes signiﬁcance vs. basal ethanol con
(P < 0.05, ANOVA followed by Tukey test). A minimum of three experimen(130 mM NaCl, 5 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 5 mM NaH-
CO3, 10 mM HEPES, pH 7.4) with 0.5 mM glucose, then loaded with
1 lg/ll Fura 2-AM in Buﬀer A for 30 min. Clusters of cells (8–15)
were selected for imaging and the cytosolic calcium was measured as
described previously [13].
2.7. cAMP measurements
INS-1 832/13 cells were seeded onto 24-well plates. The following
day the media was changed to RPMI 1640 (5 mM glucose). After
24 h incubation, cells were treated with various conditions for 15 min
in RPMI 1640 containing 2.8 mM or 15 mM glucose. All conditions,
including controls, were simultaneously treated with 100 lM IBMX.
After 15 min, 1 ml/well of 100% ethanol was added. Plates were kept
overnight at 20 C. Cell extracts were collected and cAMP levels were
measured by RIA (Biomedical Technologies).
2.8. Western blot analysis
Equivalent protein amounts were resolved using 4–12% NuPAGE
gels (Invitrogen), transferred to nitrocellulose membranes and immu-
noblotted as described previously [13]. The following primary antibod-
ies were used: guinea pig anti-insulin (Dako Inc., 1:500) and mouse
anti-c-tubulin (Sigma, T6557, 1:1000). HRP-conjugated anti-guinea
pig and anti-mouse secondary antibodies were from Jackson Immuno-
research and the enhanced chemiluminescence system was used for
detection (Amersham Biosciences).
2.9. Data analysis
Results are presented as means ± S.E. Statistical signiﬁcance be-
tween two experimental conditions was analyzed using Students t-test.
For comparisons of multiple conditions a one way ANOVA test was
performed to compare the means of the groups, followed by a Tukey
post hoc test. Diﬀerences were considered signiﬁcant at P < 0.05.3. Results
The natural product oleanolic acid has been reported to
have glucose-lowering eﬀects in vivo. A potential mechanism
by which oleanolic acid lowers blood glucose may be by
enhancing insulin secretion directly. Here we analyzed the ef-
fect of acute treatment with oleanolic acid on insulin secretion
in the glucose-responsive pancreatic b-cell line INS-1 832/13
and rat islets, and examined its possible mechanism of action.
Initial dose–response experiments indicated that oleanolic
acid enhanced both basal and glucose-stimulated insulin secre-
tion with a maximal eﬀect at approximately 50 lM. We there-
fore performed experiments examining the properties of this
compound using 30 lM and 50 lM concentrations. The eﬀect
of oleanolic acid was measured using static 1 h incubations at0
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tions. At 50 lM, oleanolic acid enhanced basal insulin secre-
tion by approximately 2-fold, whereas 30 lM oleanolic acid
had no statistically signiﬁcant eﬀect (Fig. 1A). The stimulation
of insulin secretion by oleanolic acid was comparable to that of
tolbutamide, a well characterized sulfonylurea insulin secreta-
gogue.
In addition to enhancing insulin secretion at basal glucose
levels in INS-1 832/13 cells, oleanolic acid at both 30 lM and
50 lM also enhanced glucose-stimulated insulin secretion in a
dose-dependent manner, although this was signiﬁcant only at
the higher concentration (Fig. 1A). At 50 lMoleanolic acid sig-
niﬁcantly enhanced glucose-dependent insulin secretion almost
2-fold, which was even higher than the eﬀect of the glucagon-
like peptide (GLP) -1 analogue Exendin-4 (Fig. 1B). These re-
sults show that oleanolic acid enhances both basal and glu-
cose-stimulated insulin secretion in a pancreatic b-cell line.
We also tested the eﬀect of oleanolic acid on insulin secretion
in isolated rat islets. Rat islets were incubated at basal
(2.8 mM) and stimulatory (16.7 mM) glucose for 1 h in either
the presence or the absence of oleanolic acid. Insulin secreted
into the medium was measured by radioimmunoassay. There
was no statistically signiﬁcant eﬀect of oleanolic acid at basal
glucose concentrations (Fig. 2A). However, a small (17%),
but signiﬁcant increase in the amount of insulin secreted under
glucose-stimulated conditions was observed with 30 lM olean-
olic acid. The fold increase in glucose-stimulated vs. basal insu-
lin secretion was also higher in oleanolic acid-treated islets
(Fig. 2B). These results suggest that oleanolic acid can act as
an insulin secretagogue in both rat islets and in cultured b-
cells, although the eﬀect is much more pronounced in cultured
cells. We also measured glucagon and somatostatin secretion
in rat islets but did not observe any statistically signiﬁcant ef-In
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Fig. 2. Eﬀect of oleanolic acid on insulin, somatostatin and glucagon secr
(2.8 mM) and stimulatory glucose (16.7 mM) in the presence or absence of o
secretion was measured. Results are from four independent experiments wher
The fold diﬀerence in insulin secretion between 16.7 mM and 2.8 mM glucofect of oleanolic acid (Fig. 2C and D), although glucagon
secretion tended to be higher in oleanolic acid-treated islets.
To begin to delineate the mechanism by which oleanolic acid
enhances insulin secretion secondary messenger molecules in-
volved in insulin secretion pathways were measured. Insulin
secretion occurs by a complex mechanism involving glucose
metabolism, changes in membrane potential and signaling cas-
cades involving protein kinases and a rise in cytosolic calcium
[14]. Sulfonylureas enhance insulin secretion under basal glu-
cose conditions by binding to and inhibiting plasma membrane
K+ channels, leading to Ca2+ inﬂux and ultimately insulin
secretion [1]. Increased intracellular Ca2+ at the cell surface
stimulates granule fusion with the plasma membrane resulting
in insulin exocytosis [14]. Since oleanolic acid enhanced insulin
secretion at basal glucose in INS-1 832/13 cells, we tested
whether intracellular Ca2+ levels increased under these condi-
tions. As shown in Fig. 3A and B, oleanolic acid did not aﬀect
intracellular Ca2+ levels, unlike tolbutamide which resulted in
a rapid cytosolic Ca2+ increase.
Oleanolic acid enhanced insulin secretion under glucose-
stimulated conditions in both INS-1 832/13 cells and rat islets
and this eﬀect was similar to the incretin Exendin-4 (Fig. 1B).
Exendin-4 is a GLP-1 analogue that potentiates insulin secre-
tion by binding the GLP-1 receptor and increasing intracellu-
lar cAMP levels [15]. We therefore tested the eﬀect of oleanolic
acid on cAMP levels in INS-1 832/13 cells. Cells were stimu-
lated with either oleanolic acid or Exendin-4 for 15 min in
the presence of IBMX to prevent cAMP degradation. Unlike
Exendin-4 which caused an increase in cellular cAMP levels
under stimulatory glucose conditions, there was no eﬀect with
oleanolic acid treatment (Fig. 3C).
In addition to the acute eﬀects of oleanolic acid on insulin
secretion, we also explored the eﬀect of chronic administration0
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Fig. 3. Eﬀect of oleanolic acid on cytoplasmic Ca2+ and cAMP levels in INS-1 832/13 cells. (A) Cytoplasmic Ca2+ levels were monitored in buﬀer
containing 0.5 mM glucose and oleanolic acid (OA), tolbutamide and ionomycin were added directly to cells during imaging as indicated. A
representative trace is shown. (B) A summary of multiple experiments is shown (means ± S.E.). The 0.5 mM glucose condition is the average ratio
(340 nm/380 nm) 10 s prior to subsequent treatments. The 50 lM oleanolic acid (OA) condition is the peak ratio within 50 s of administering
oleanolic acid. The 300 lM tolbutamide condition was similarly calculated. The 50 lM oleanolic acid (15 min) condition shows the average
ﬂuorescence ratio after 15 min treatment. * denotes P < 0.05 ANOVA followed by Tukey test. (C) Cells were treated with 50 nM Exendin-4 (Ex-4) or
50 lM oleanolic acid (OA) for 15 min. All groups were simultaneously treated with 100 lM IBMX. cAMP levels were measured by RIA. Data points
are shown as the fold over the 2.8 mM glucose control condition from four experiments. * denotes signiﬁcance vs. 15 mM glucose control (P < 0.05,
ANOVA followed by Tukey test).
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These cells were used because they express only endogenous rat
insulin genes in contrast to the INS1 832/13 cell line, which
also stably expresses the human proinsulin gene [10]. INS-1
cells were treated with 30 lM and 50 lM oleanolic acid or eth-
anol solvent control for 6–48 h. Cellular insulin content was
measured by radioimmunoassay. Interestingly, treatment with
oleanolic acid enhanced steady-state insulin protein levels by
approximately 20–25% with 48 h of treatment (Fig. 4A and
B). Western blot analysis also detected an increase in proinsu-
lin levels with 48 h treatment with oleanolic acid (Fig. 4C).
To determine if this increase in insulin levels occurs at the
transcriptional level insulin mRNA was measured. Rat insu-
lin-2 gene expression was measured in control INS-1 cells
and cells treated for various times with 30 lM oleanolic acid.
Total RNA was isolated and real-time PCR analysis was per-
formed using insulin-2 speciﬁc primers. Glucose is known to
stimulate insulin gene transcription [16] and indeed there was
an increase in insulin-2 mRNA levels after a 2 h treatment at
stimulatory glucose concentrations (Fig. 4D). Interestingly,
insulin-2 mRNA was also elevated in cells treated with olean-
olic acid. After 48 h treatment with oleanolic acid there was an
2-fold increase in insulin-2 mRNA levels relative to control-
treated cells.4. Discussion
Oleanolic acid is a triterpenoid natural product found in a
variety of plants and has been demonstrated to have a variety
of biological eﬀects. Interestingly, both oleanolic acid and ole-
anolic acid glycosides have been shown to have glucose-lower-
ing properties in animal models in vivo. The mechanism by
which oleanolic acid reduces glycemia is not established. Sev-
eral possibilities have been identiﬁed including eﬀects on reduc-
ing gastric emptying [6], enhancing acetylcholine release that in
turn may augment insulin release [7], or reducing insulin resis-
tance [8]. A recent study using the glucose unresponsive pan-
creatic beta cell line RINm5F has also suggested that
oleanolic acid may stimulate insulin secretion [17].
Here we examined the insulin secretagogue properties of ole-
anolic acid using a glucose-responsive pancreatic b-cell line
INS-1 832/13 and isolated rat islets. We found that oleanolic
acid promotes acute insulin secretion at both basal glucose lev-
els as well as under stimulatory conditions in INS-1 832/13
cells. The magnitude of the insulin secretion stimulation was
similar to the sulfonylurea tolbutamide at basal glucose levels
and to that of the incretin mimetic Exendin-4 at glucose-stimu-
lated conditions. Importantly, we also observed a stimulatory
eﬀect on insulin secretion in rat islets, although the eﬀect was
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Fig. 4. Eﬀect of chronic oleanolic acid exposure on insulin protein and mRNA content in INS-1 cells. Cells were treated for various time points with
(A) 30 lM oleanolic acid or the solvent only (n = 4), and (B) 50 lM oleanolic acid or the solvent only (n = 3). Insulin was measured by RIA. Data is
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glucose concentrations. Oleanolic acid did not increase somato-
statin secretion, which is known to inhibit insulin secretion,
thus the reason for the diﬀerences observed between cultured
b-cells and primary islets is unknown. It is important to note
that the concentration of oleanolic acid used to observe eﬀects
on insulin secretion in vitro (13 lg/ml) are50–100 fold high-
er than those reported in rodent plasma after oral administra-
tion of oleanolic acid at doses that lower plasma glucose
levels in vivo [8,18]. Thus, direct eﬀects of oleanolic acid on
b-cell insulin secretion may not account for the anti-diabetic
properties of this substance when given orally in vivo [8].
Regardless, our results suggest that oleanolic acid does pos-
sess insulin secretagogue properties. As a ﬁrst approach in
determining the mechanism by which oleanolic acid enhances
insulin secretion, we measured both intracellular Ca2+ and
cAMP levels in oleanolic acid treated INS-1 832/13 cells. Un-
like tolbutamide or Exendin-4, which elevated cellular Ca2+
and cAMP levels, respectively, oleanolic acid did not aﬀect
these parameters and thus likely enhances insulin secretion
through other mechanisms.
One proposed mechanism by which oleanolic acid and its
derivatives aﬀect cell pathways is by modifying protein activity
directly by Michael addition, a chemical reaction between a
nucleophile such as an –SH group and an unsaturated car-
bonyl such as that found in oleanolic acid [19]. Thus, oleanolic
acid may react with exposed –SH groups and thereby poten-
tially alter the activity of proteins in the insulin secretory path-
way. Oleanolic acid has been shown to inhibit a-glucosidase
[20] and activate the TGR5 G-protein couple receptor [8],
which may contribute to oleanolic acids glucose-lowering ef-
fects by reducing glucose adsorption and increasing insulinsensitivity. The protein targets that are modiﬁed in the b-cell
that cause enhanced secretion still need to be identiﬁed.
Synthetic oleanane triterpenoids derived from oleanolic acid
having two carbonyl bonds have recently been synthesized that
have more potent properties than the parent molecule [5,19].
Some of these derivatives, such as 2-cyano-3, 12-dioxoole-
ana-1,9(11)-dien-28-oic acid (CDDO), have potent anti-inﬂam-
matory and anti-cancer as well as pro-apoptotic properties
depending on the concentration used. Some of the target en-
zymes of these derivatives have been identiﬁed and include
transcription factors, IKK, cyclins, among other targets [5].
In future studies it will be interesting to examine the eﬀects
of these synthetic oleanolic acid derivatives on insulin secretion
in pancreatic b-cells.
In addition to the acute eﬀects of oleanolic acid on insulin
secretion, we also examined the eﬀect of chronic administra-
tion of oleanolic acid on cellular insulin mRNA and protein
levels, to determine if elevated secretion is paired with en-
hanced insulin synthesis. Interestingly, chronic treatment of
oleanolic acid enhanced both insulin mRNA and protein levels
in the INS-1 cell line. Although the eﬀect was not observed un-
til 48 h of treatment, it is apparent that oleanolic acid is able to
increase steady-state insulin levels. The mechanism by which
oleanolic acid increases insulin mRNA levels requires future
study. In addition, it will be interesting to examine if the more
potent derivatives of oleanolic acid have this eﬀect.
In summary, we show here that oleanolic acid acts as an
insulin secretagogue in vitro and is able to stimulate insulin
secretion at both basal and glucose-stimulated conditions in
cultured cells. In rat islets the eﬀect was modest suggesting that
this may not be the primary mechanism by which oleanolic
acid lowers glycemia in vivo. Current eﬀorts are underway to
1380 T. Teodoro et al. / FEBS Letters 582 (2008) 1375–1380examine the eﬀects of synthetic oleanane derivatives in search
of more potent stimulators of pancreatic b-cell function.
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